Gujarat Themis Biosyn Q1 FY27 profit rises 22%

What was announced

Gujarat Themis Biosyn Ltd reported higher profitability for the quarter ended June 30, 2026 (Q1 FY27), with net profit rising year-on-year and operating margins improving. The company also disclosed proceedings of an Extraordinary General Meeting (EGM) held on August 22, 2026.

The quarterly update is based on unaudited standalone and consolidated financial results. The Board of Directors approved these results on August 7, 2026, after review by the Audit Committee and statutory auditors GMJ & Co.

Q1 FY27: top line growth with stronger operating margin

For Q1 FY27, Gujarat Themis Biosyn reported income from operations of ₹43.79 crore, compared with ₹35.87 crore in Q1 FY26. The company reported a 22% year-on-year increase in standalone net profit to ₹11.07 crore for the quarter ended June 30, 2026.

Profitability improved at the operating level as well. EBITDA for Q1 FY27 came in at ₹20.79 crore, and the EBITDA margin expanded to 47.5% from 38.8% a year earlier. Profit before tax (PBT) for the quarter was ₹15.17 crore.

The company reported EPS of ₹1.02 for Q1 FY27, compared with ₹0.83 in Q1 FY26.

Quarterly cost and profit snapshot from reported financials

The reported quarterly financial summary for June 2026 also shows operating leverage compared with June 2025. Revenue for the June 2026 quarter is shown at ₹44 crore versus ₹36 crore in June 2025, while expenses moved to ₹23 crore from ₹22 crore.

EBITDA rose to ₹21 crore in June 2026 from ₹14 crore in June 2025, and operating profit percentage increased to 47% from 39%. Depreciation for June 2026 was ₹4 crore, interest was ₹2 crore, and net profit was ₹11 crore.

Standalone and consolidated: figures cited in the release

The company’s reported consolidated quarterly numbers for June 2026 include net sales of ₹43.79 crore, net profit of ₹11.07 crore, and EBITDA of ₹20.92 crore. The release also notes that EPS increased to ₹1.02 in June 2026 from ₹0.83 in June 2025.

While the narrative highlights a 22% year-on-year rise in profit and income from operations, it also points to a sharp improvement in EBITDA versus the year-ago quarter.

How Q1 FY27 compares with Q4 FY26

Sequentially, income from operations was broadly steady versus the March 2026 quarter. The company reported income from operations of ₹44.23 crore in Q4 FY26 and ₹43.79 crore in Q1 FY27.

EBITDA improved from ₹19.36 crore in Q4 FY26 to ₹20.79 crore in Q1 FY27, with margin moving up from 43.8% to 47.5%. Net profit after tax rose slightly from ₹10.89 crore in Q4 FY26 to ₹11.07 crore in Q1 FY27.

Key quarterly metrics table

FY26 full-year picture: revenue up, PAT lower

For FY26 (financial year ended March 31, 2026), Gujarat Themis Biosyn reported revenue from operations of ₹165.8228 crore, with an EBITDA margin of 45.55%. PAT for FY26 was ₹46.6815 crore, down from ₹48.7717 crore in FY25.

The company also reported total income of ₹168.2509 crore for FY26 compared with ₹153.2323 crore in FY25. Earnings per share for FY26 was reported at ₹4.28 versus ₹4.48 in FY25.

Dividend and other board decisions cited

For FY26, the Board meeting held on May 25, 2026 approved audited financial results and recommended a final dividend of Re 0.67 per equity share.

Separately, the Board approved the appointment of M/s Raja Dutta & Co., Cost Accountants, as Cost Auditor for the financial year 2026-27.

Capacity increase disclosed for FY26

The company’s disclosed capacity figures show a sizeable increase from FY25 to FY26. Capacity is reported at 450.00 KL in FY25 and 990.00 KL in FY26.

The release does not provide additional operating commentary in the extracted text, but the step-up in capacity is a key datapoint alongside the margin-led improvement visible in quarterly numbers.

EGM proceedings and stock reference levels

The filing also references proceedings of an EGM held on August 22, 2026. Alongside this corporate action entry, the provided data lists the last traded price (LTP) on the announcement day and the record day.

Based on the table, the stock’s LTP is shown at ₹351.50 on August 22, 2026 and ₹381.20 on the record day.

Market impact and why the numbers matter

The headline takeaway from Q1 FY27 is that profit growth was supported by a higher operating margin, with EBITDA margin reported at 47.5% versus 38.8% in the year-ago quarter. The quarterly data also indicates higher EBITDA and net profit compared with June 2025.

For investors tracking consistency, the comparison with Q4 FY26 shows a relatively stable revenue base quarter-on-quarter, while margins improved. For longer-term context, FY26 reported revenue from operations increased versus FY25, but FY26 PAT was lower than the previous year.

Conclusion

Gujarat Themis Biosyn’s Q1 FY27 update shows a 22% year-on-year rise in net profit and an improvement in EBITDA margin, alongside board approvals for unaudited results dated August 7, 2026. Separately, the company has disclosed EGM proceedings held on August 22, 2026, with LTP reference levels provided for the announcement and record dates.